Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations,Highlighting Mechanism of Action and Clinical Activity of,Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American,Diabetes Association 67th Scientific Sessions in Chicago, Illinois

rest include: 2220 - Oral Administration of Sulodexide for the Treatment of Diabetic Nephropathy in a Phase II Study has Minimal to No Effect on Coagulation or Fibrinolytic Activity JULIA LEWIS, ITAMAR RAZ, SHERWYN SCHWARTZ, STEPHEN ARONOFF, MURRAY KATZ, GILBERT EISNER, JAMES MERSEY, Nashville, TN, Jerusalem, Israel, San Antonio, TX, Dallas, TX, Tucson, AZ, Washington, DC, Baltimore, MD 2376 - Efficacy and Safety of Sulodexide in the Treatment of Diabetic Nephropathy RAM WEISS, ROBERT M. NIECESTRO, ITAMAR RAZ, Jerusalem, Israel, New York, NY

ABOUT SULONEX(TM)

Sulonex (sulodexide oral gelcap) belongs to a proposed new class of nephroprotective, or kidney protecting, drugs, known as the glycosaminoglycans. A variety of members of this chemical family have been shown to decrease pathological albumin excretion in diabetic nephropathy in humans. Some of the members of this chemical family include the following approved drugs: standard heparin, low molecular weight heparin and danaparoid. These agents all require therapy by injection and are all potent anticoagulants, which are blood thinners capable of inducing bleeding. Sulonex, on the other hand, is given orally and, in this form, has demonstrated little, if any, anticoagulant effects to date.

Keryx owns the exclusive rights to use Sulonex(TM) for the treatment of diabetic nephropathy in North America, Japan and certain other markets outside of Europe. Diabetic nephropathy is a long-term complication of diabetes in which the kidneys are progressively damaged. Sulonex is a glycosaminoglycan compound with structural similarities to the broad family of marketed heparins and low molecular weight heparins. This drug has been marketed in a number of European, Asian and South American countries for many years by our licensor for certain cardiovascular conditions and has an established safety profile at
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
Breaking Medicine Technology:Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5Nplate(R) Data From MDS Studies Presented at ASH 2Nplate(R) Data From MDS Studies Presented at ASH 3Nplate(R) Data From MDS Studies Presented at ASH 4Nplate(R) Data From MDS Studies Presented at ASH 5Nplate(R) Data From MDS Studies Presented at ASH 6Nplate(R) Data From MDS Studies Presented at ASH 7Nplate(R) Data From MDS Studies Presented at ASH 8Nplate(R) Data From MDS Studies Presented at ASH 9Nplate(R) Data From MDS Studies Presented at ASH 10Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2New and Updated Online Tutorials for ArrayExpress Allen Brain Atlas and CleanEx from OpenHelix 54389 1New and Updated Online Tutorials for ArrayExpress Allen Brain Atlas and CleanEx from OpenHelix 54389 2New and Updated Online Tutorials for ArrayExpress Allen Brain Atlas and CleanEx from OpenHelix 54389 3Cancer Mortality Rates Experience Steady Decline 54386 1Cancer Mortality Rates Experience Steady Decline 54386 2Cancer Mortality Rates Experience Steady Decline 54386 3Cancer Mortality Rates Experience Steady Decline 54386 4APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 54384 1APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 54384 2